ValiRx confident in two ongoing clinical trials

ValiRx was confident in the potential of two of its compounds on Tuesday, in its quarterly update on its ongoing clinical trials.

The AIM-traded life science firm, with a focus on cancer diagnostics and therapeutics for personalised medicine, said that recent testing had shown VAL201 to be well-tolerated up to a putative therapeutic dose and has shown a high degree of safety.

ValiRx said the readout from the first part of the trial - from first-in-human dosing through to a therapeutically meaningful dose - has shown strong safety and tolerability in all trial subjects.

"In light of the excellent results shown by the compound with respect to tolerability and safety in the current clinical trial, along with promising pre-clinical evidence of the compound's efficacy with respect to the treatment of endometriosis, the company has started the design of the protocol to test VAL201 for its in-human potential in the treatment of the debilitating female condition", the board added.

ValiRx said it had already shown good pre-clinical results for that indication.

The company's other ongoing trial - VAL401 - was described was described as a study to assess the efficacy, safety and tolerability of VAL401 in the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), after failure of at least one prior chemotherapeutic regimen.

It had been registered with the European Union Drug Regulation Authorities Clinical Trials Database, and work was now continuing to advance the regulatory approval process, with a preliminary trial site and Principal Investigator successfully engaged.#

At 1315 GMT, shares in ValiRx were up 11.67% to 16.75p.